Research programme: next-generation hepatitis C virus therapeutics - Shire/Wyeth

Drug Profile

Research programme: next-generation hepatitis C virus therapeutics - Shire/Wyeth

Latest Information Update: 22 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ViroPharma; Wyeth
  • Class Benzofurans; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 16 Apr 2008 Discontinued - Preclinical for Hepatitis C in USA (unspecified route)
  • 16 Feb 2005 A potential drug candidate (HCV 796) has been selected for further development
  • 07 Jan 2005 Wyeth has filed an IND with the FDA in USA for Hepatitis C
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top